and a little more for you @sylau90 and the clown troopyou should...

and a little more for you @sylau90 and the clown troop

you should not be investing in pharma R&D stock on startups - you have no concept twhere the value will be realised or how that will occur.

answer - HUMAN DATA
big pharma move on human data only out of phase IIIs'
Bob Clark joined based on the human data he witnessed as a comparison to his years of pharma expertise
The John Hopkins affiliates came on board due to the quality of the early human data they were privy too
I could keep listing but I'm sure you get the idea where its going
etc etc

human data out the end of phase IIIs' that meet and exceed endpoints move R&D pharma startups north and very very little else ....when that happens you don't want to be on some backwater stock board that offers 11.5b in pharma revenu into 2025/26 do you....you'd prefer to be levelraging a 600b pharma revenue opportunity into 2025/26 ......or nope, maybe the clown troop can't understand that very simple market + business equation

go figure...lol